HEPATITIS B: PREGNANCY AND LABOR MANAGEMENT MICHAEL P. NAGEOTTE, M.D.
|
|
- Shonda Morrison
- 6 years ago
- Views:
Transcription
1 HEPATITIS B: PREGNANCY AND LABOR MANAGEMENT MICHAEL P. NAGEOTTE, M.D.
2 Disclosures I have no relevant financial relationships to disclose or conflicts of interest to resolve. I will not discuss any unapproved or off label, experimental or investigational use of a product, drug, or device.
3 HEPATITIS B VIRUS (HBV) Caused by the hepatitis B virus (HBV) HBV is a double-stranded DNS virus that primarily effects the liver The HBV virion is also known as the Dane particle
4 Small DNA virus Three principle antigens Surface antigen (HBsAg) Core antigen (HBcAg) Hepatitis B e antigen (HBeAG) What is Hepatitis B?
5 HBV DNA ENCODES: HBV polymerase (enzyme with reverse transcriptase activity) Hepatitis B core antigen (HBcAg) Pre-core protein cleaved in the endoplasmic reticulum of the infected cell and secreted as hepatitis B e antigen (HBeAg) Large, middle and small surface antigens (HBsAg) The X protein; required to initiate and maintain virus replication after infection
6 INFECTION Sexual transmission accounts for most HBV infections in the U.S. Risk is 25% for regular sexual contacts of infected individuals to become seropositive; chronic HBV has 15-25% mortality from cirrhosis or hepatocellular carcinoma; 250 million people worldwide with chronic HBV Mother to child transmission is the predominate mode of transmission in areas of high HBV prevalence (Asia, Africa and South Pacific) Vertical transmission can occur in 10% of neonates with first trimester acute infection and in 80-90% with third trimester acute infection In women chronically seropositive for both HBsAg and HBeAg, vertical transmission occurs in approximately 90% 10-20% of HBsAg seropositive women will transmit the virus to their neonates in the absence of immunoprophylaxis; neonatal/pediatric acquisition additional risk without vaccination
7 INFECTION Average incubation period is 90 days from exposure to symptoms but may vary from 6 weeks to 6 months HBV found in highest concentrations in the blood with lower concentrations in saliva, semen, vaginal secretions and wound exudates HBV can remain viable on environmental surfaces or at room temperature for greater than 7 days Acute HBV infection in adults is symptomatic in only 50% (anorexia, nausea, vomiting, fever, abdominal pain and jaundice); 1% of cases result in acute liver failure and death Chronic infection occurs in 90% of infected infants, 30% of infected children < 5 years and 2% - 6% of adults
8
9 Acute Hepatitis B with Recovery
10 Progression to Chronic Hepatitis B
11
12 Adult Infection Mortality associated with Hepatitis B is only 1% Of adults infected, 85-90% have resolution However, 2% - 6% develop chronic infection 15-30% of chronically infected have continued viral replication with persistence of the e Ag Develop cirrhosis and persistent hepatitis Can develop hepatocellular carcinoma Likely have high viral DNA load
13 Acute Hepatitis in Pregnancy As with any adult, hospitalize with: Encephalopathy Coagulopathy Severe debilitation Correct coagulopathy Supportive care/limit activity Protect from upper abdominal trauma
14 Prenatal Diagnostic Testing Transmission through amniocentesis or CVS appears low with chronic Hepatitis B or C 115 women known HBsAg positive at test Neonatal infection rates were no different However, very small number of cases Alternative genetic screening options should be considered
15 Efforts to Mitigate Risk of Vertical Transmission of Hepatitis B During Pregnancy and Birth
16 Immunization of Neonates Screen negative (HBSAg negative) mother: active immunization before discharge but no later than 2 months of age; total of three injections at 0, 1 and 6 months Neonates <2000 gms with negative mother, vaccine should be delayed until 1 month of age or discharge with subsequent vaccination
17 Vaccination Seroconversion occurs in 95% of recipients Should be given in the deltoid Intragluteal and intradermal injections result in lower rates of seroconversion
18 Immunization of Neonates HBsAg positive or unknown at delivery HBIG (0.6 ml/kg) plus-- Hepatitis B vaccine Give simultaneously at different sites IM Give within 12 hours of birth Two more Hepatitis B vaccines within 6 months Immunoprophylaxis will do nothing if the neonate was already infected in utero
19 INFECTION Immunoprophylaxis failure against vertical transmission appears to occur more frequently in mothers who are HBeAg-positive and/or have high viral loads The presence of HBeAg generally indicates the person has high levels of virus and greater infectiousness; the absence of e-antigen does not exclude active viral replication Maternal HBV-DNA level has been demonstrated to be the strongest predictor of neonatal immunoprophylaxis failure, with a lower prophylaxis effective rate directly related to a higher maternal viral load/positive HBeAg status
20 In Utero Fetal Infection 85-95% of perinatal transmission occurs intrapartum from infected maternal blood and GU secretions 5-15% are from hematogenous transplacental dissemination and postnatal contact Risks for in utero infection include: Threatened preterm labor/maternal hemorrhage Higher HBsAg and HBV DNA titres HBeAg positivity HBV DNA in villous capillary endothelial cells
21 Failure of Immunoprophylaxis at Birth What can be done to limit the in utero acquisition of hepatitis B? Is post-exposure prophylaxis indicated in pregnancy? Are there specific risk factors or populations which are at greater risk for infection before labor and delivery? Is there any evidence of efficacy with antenatal treatment resulting in a lower failure of immunoprophylaxis at birth?
22 Prophylaxis for Susceptible Pregnant Women Sexual contact, percutaneous or mucosal exposure, needle sharing or sexual assault/abuse with HBSAg-positive individual within 14 days: --if previously vaccinated, administer hepatitis B vaccine booster dose --if unvaccinated, administer hepatitis B vaccine series and HBIG --if contact has unknown HBSAg status, no treatment if previously vaccinated; hepatitis B vaccine series if unvaccinated
23 Antepartum Fetal Therapy--HBIG Randomized 112 women into: HBIG treatment q4 weeks from 28 weeks Control group IU infection rate 10.5% vs 27.3% (p<0.05) Ascendant trend as HBV DNA levels increases Risk increases with HBV-DNA > 10 8 copies/ml Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, Teng BQ. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol. 2004;10(21):3215.
24 Antiviral Treatment in Pregnancy Indications for treatment: Chronic liver disease in the mother Decrease the vertical transmission rate Can we affect the intrauterine fetal infection rate by treating mother during pregnancy?
25 Nuceloside Analogues Lamivudine Category C History of safety in HIV infection but high risk for resistance Tenofovir Category B First line agent and low risk for resistance Telbivudine Category B High risk for resistance and very few studies of efficacy
26 Antepartum Treatment: HBIG or Lamivudine HBIG group 56 cases Q4 weeks: 28 weeks until delivery Lamivudine 43 cases 100 mg daily: 28 weeks to 30 days after labor Control group 52 cases No specific treatment HBsAg, HBeAg, HBV-DNA tested 28 weeks Before delivery In newborns 24 hour before immunoprophylaxis Li XM, Yang YB, Hou HY, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003 Jul;9(7):
27 Antepartum Treatment Group n HBsAg (+) n HBeAg (+) n Intrauterine infection n % HBIG a Lamivudine a Control b a P>0.05 between HBIG and lamivudine group; b P<0.05 Control vs HBIG or lamivudine group Li XM, Yang YB, Hou HY, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003 Jul;9(7):
28 ANTEPARTUM HBIG vs. LAMIVUDINE Rate of neonatal HBV positivity 16.1 % in HBIG group vs. 16.3% in lamivudine group vs.32.7% in controls HBV DNA significantly reduced in both treatment groups compared to controls Despite immunoprophylaxis, there continued to be a significant rate of newborn HBSAg positivity
29 Antepartum Lamivudine Treatment Multi-center, double blind, RCT of 155 HBSAg + mothers Arm 1: lamivudine + infant HBIG/vaccine (n=89) Arm 2: placebo + infant HBIG/vaccine (n=61) Arm 3: lamivudine + infant vaccine only 154/155 were HBeAg positive Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94.
30 HBV DNA Level Lamivudine (n=89) Placebo (n=61) n Mean (SD) Meq/mL n Mean (SD) Meq/mL Baseline (1610.9) (1627.0) Week 4 (ante) (177.4) (1447.6) Week 8 (ante) (93.5) (1480.1) At labor and delivery (308.5) (1646) Week 4 (pp) *End of tx (760.6) (3274.5) Week 9 (pp) (3200.4) (2446) Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94.
31 Results At birth: 7/56 (12.5%) of infants in the lamivudine group were HBsAg seropositive 14/59 (24%) infants in the placebo group At 52 weeks: 10/56 (18%) of infants in the lamivudine group were HBsAg seropositive 23/59 (39%) in the placebo group (p = 0.014) Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94.
32 Antepartum Lamivudine Treatment Meta-analysis of 15 RCTs 1693 HBV carrier mothers Started treatment at 28 weeks Interruption of MTCT at birth and at 6-12 months of age Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011; 17(38):
33
34
35
36
37
38 Concluded Lamivudine treatment from 28 weeks of gestation efficiently interrupts MTCT Treatment is safe and more efficient than HBIG at delivery in interrupting MTCT If maternal viral load is reduced to < 10 6 copies/ml by lamivudine treatment, HBV MTCT can be more frequently prevented
39 Antepartum Lamivudine Treatment Meta analysis of 10 RCTs including 951 mothers Included studies with an HBIG arm Interruption of intrauterine infection significant Interruption of MTCT at 9-12 months significant Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147.
40 Lamivudine versus control for interruption of intrauterine infection Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147.
41 Lamivudine versus HBIG for interruption of intrauterine infection Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147.
42 Lamivudine vs. control in interruption of HBV mother-to-child transmission at 9 12 months Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147.
43 Concluded Lamivudine is effective in interruption of HBV intrauterine infection and MTCT at 9-12 months Should be recommended to mothers with viral loads of >10^3 copies/ml Problem is with establishment of high resistance to lamivudine treatment in high percentage of patients Not recommended antiviral because of this concern
44 Current Interventions HBIG and HBV vaccination at birth Decreased the MTCT to 5-10% 8-30% of mothers with HBeAg positivity or high viral loads still pass HBV to their babies What options are there for treating in utero? Maternal HBIG administration Maternal antiviral treatment--options
45 Which Fetuses are at Higher Risk of Intrauterine Infection? Two nested case-control studies in 773 hepatitis B surface antigen (HBsAg)-positive Taiwanese women and their infants As the serum HBV DNA levels increased: HBeAg positive moms: OR increased from for persistent neonatal infection HBeAg negative mom: OR 19 for high vs low viral load Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis. 1994;170(6):1418.
46 Failure of Neonatal Treatment Retrospective review between HBsAg + mother infant pairs Dose dependent correlation with HBV-DNA levels and neonate immunoprophylaxis failure All failed cases had mothers with HBeAg positivity and high DNA levels (>10 6 copies/ml) Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19(2): e18 e25.
47 Failure of neonatal treatment Meta-analysis in the Netherlands HBV-DNA level was only factor affecting treatment efficacy 100% efficacy with viral DNA levels < 10 7 IU/mL at birth 68% efficacy with viral DNA levels > 10 7 IU/mL at birth del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol 1994; 20(4):
48 HBV DNA Viral Load Observational study within Kaiser Northern California 4446 infants born to 3253 HBV positive mothers Viral load determined in third trimester in all patients ; all neonates treated with HBIG and vaccine Lowest viral load with transmission was 6.32 x 10 7 IU/mL No mother with viral load less than 5 x 10 7 IU/mL transmitted the virus regardless of HEV status Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med Jun;160(12):
49 Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load (Pan, CQ, Duan Z, Dai, E, et al. N Engl J Med 2016; 374: ) 200 mothers positive for HBeAg with HBV DNA level higher than 200,000 IU/ml (between 5 and 6 log 10 copies/ml) Randomized to usual care or tenofovir disoproxil fumarate (TDF) 300 mg/day from weeks of gestation until postpartum week 4 All infants received immunoprophylaxis Primary outcomes were the rates of MTCT and birth defects Secondary outcomes were safety of TDF, % of mothers with an HBV DNA level less than 200,000 IU/ml at delivery and loss or conversion of HBeAg or HBSAg at postpartum week 28
50 RESULTS At delivery, 68% in the TDF group (66 of 97 women) as compared with 2% in the control group (2 of 100) had an HBV DNA level less than 200,000 IU per ml (P<0.001) At postpartum week 28, the MTCT was significantly lower in the TDF group than in the control group, both in the intention-to-treat analysis (with transmission of virus to 5% of infants [5 of 97] vs. 18% [18 of 100], P=0.007) and the per-protocol analysis (with transmission of virus to 0 vs. 7% [6 of 88], P=0.01). Maternal and infant safety profiles similar although more mothers in the TDF group had an increase in the creatine kinase level and elevated LFTs. The maternal HBV serologic outcomes did not differ significantly between the groups.
51 CONCLUSIONS In a cohort of HBeAg-positive mothers with and HBV DNA level of more than 200,000 IU/ml during the third trimester, the rate of MTCT was significantly lower among those who received TDF therapy than among those who received usual care without antiviral therapy There were no differences in the maternal and infant safety profiles; this included birth defects but there was noted an increase in maternal creatine kinase and alanine aminotransferase (SGPT) both during and following TDF treatment
52 STUDY CONCERNS Was initiation of TDF therapy done too late? Current international guidelines recommend that antiviral treatment start at weeks. Would earlier treatment further reduce the almost one third of mothers who continued to have levels above the HBV DNA threshold? Was avoidance of breast-feeding while taking TDF appropriate? Women being treated with TDF-containing antiretroviral regimens for HIV are encouraged to breast-feed. In this report, 49% of the infants in the TDF group and 57% in the control group were born by cesarean section. The rate of elective cesarean section was 34% (67 of 197) with the TDF rate no different from the control (64% [30 of 47 mothers] and 74% [37 of 50], respectively; P=0.28). Did bias effect the choice of elective cesarean section and effect in any way the results?
53 CURRENT TREATMENT RECOMMENDATIONS SMFM recommends antiviral therapy be considered in pregnant women with HBV infection and viral load > 6-8 log 10 copies/ml; currently no official ACOG position Consider HBeAg as well as HBV DNA level in HBSAg positive women in second trimester of pregnancy, particularly if first generation immigrants from SE Asia or Africa Antiviral treatment generally started at 28 weeks with the nucleotide analogue tenofovir disoproxil fumarate (TDF) 300 mg orally/day until delivery as the preferred antiviral because of its better resistance profile and safety data in pregnancy Delivery by cesarean section for the purpose of reducing MTCT of HBV is not recommended by the CDC or ACOG
54
55 Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10(5):
56 THANK YOU!
57 Vertical Transmission Perinatal transmission is the greatest cause of chronic infection worldwide Without prophylaxis at birth: 10-20% seropositive for HBsAg alone will transmit the virus to their neonates 90% of women seropositive for HBsAg AND HBeAg will transmit the virus to the neonate
58 Adult versus Perinatal Acquisition Risk of developing chronic HBV is inversely proportional to the age at exposure Risk of chronic infection for adults is 5-10% If acquired perinatally: Risk of chronic infection is 85-95% 25-30% lifetime risk of serious or fatal liver disease
59 Vertical Transmission Gestational age timing of maternal acute hepatitis B affects the transmission rate: 1 st trimester: up to 10% of patients will be seropositive at delivery (+ HbSAg) 3 rd trimester: 80-90% of patients will be seropositive at delivery
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationThe Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections
The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections Neil S. Silverman, M.D. Center for Fetal Medicine and Women s Ultrasound Clinical Professor, Obstetrics/Gynecology David Geffen
More informationShould we treat hepatitis B positive pregnant women to prevent mother to child transmission?
Should we treat hepatitis B positive pregnant women to prevent mother to child transmission? Daniel Shouval Liver Unit Hadassah-Hebrew University Hospital Jerusalem, Israel VHPB Vienna June 1-2, 2017 Background
More informationObstetricians and gynecologists knowledge, education, and practices regarding chronic hepatitis B in pregnancy
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 670-674 Obstetricians and gynecologists knowledge, education, and practices regarding chronic hepatitis B in pregnancy Bolin Niu a, Dina Halegoua-De
More informationChronic Hepatitis B in Pregnancy
Chronic Hepatitis B in Pregnancy Tatyana Kushner M.D., M.S.C.E., * and Monika Sarkar M.D., M.A.S. More than 250 million individuals worldwide are infected with chronic hepatitis B virus (HBV), including
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationHepatitis B Virus in Pregnancy
REVIEW REVIEW Hepatitis B Virus in Pregnancy Tram T. Tran, M.D. Chronic hepatitis B virus (HBV) infection remains an important worldwide cause of chronic liver disease, which may lead to the development
More informationLiver and pregnancy part 2 : pregnancy in patient with underlying liver disease
Liver and pregnancy part 2 : pregnancy in patient with underlying liver disease Ahmad Shavakhi.MD Associate professor Isfahan university of medical sciences Pregnancy in cirrhosis Pregnancy is a rare event
More informationPregnancy and Hepatitis B
Pregnancy and Hepatitis B Resat Ozaras, MD, Professor Istanbul University Cerrahpasa Medical School Infectious Diseases Dept. Istanbul, TURKEY 25.0 20.0 15.0 10.0 5.0 0.0 HBV Prevalence in Pregnant Women
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationElimination of Perinatal Hepatitis B Transmission
Elimination of Perinatal Hepatitis B Transmission Trudy V. Murphy, MD Division of Viral Hepatitis NCHHSTP, CDC December 19, 2013 Hep B United and WHIAAPI Webinar Background q Hepatitis B is an infection
More informationHepatitis and pregnancy
Hepatitis and pregnancy Pierre-Jean Malè MD Training Course in Reproductive Health Research WHO Geneva 2008 26.02.2008 Liver disease and pregnancy: three possible etiologic relationship the patient has
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationTreatment of hepatitis B : the guidelines and real life
Treatment of hepatitis B : the guidelines and real life Prince of Songkla University, Thailand Teerha Piratvisuth MD. NKC Institute of Gastroenterology and Hepatology Disclosure Statement of Financial
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis
More informationHBsAg(+) mothers is a transient
Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection transmission Vana Papaevangelou (Greece) National and Kapodistrian University
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationBlood-Borne Viruses and Pregnancy. Prof Ashley Brown Imperial Healthcare NHS Trust
Blood-Borne Viruses and Pregnancy Prof Ashley Brown Imperial Healthcare NHS Trust Hepatitis B and Pregnancy Global Prevalence of Chronic HBV Chronic HBV prevalence (% of population) Chronic HBV in the
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationCarrier state and chronic infection state. At-risk populations
John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology and Nutrition Carrier state and chronic infection state -
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationObstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School
Obstetric Complications in HIV-Infected Women Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School Obstetric Complications and HIV Obstetric complications are not increased in
More informationA study on hepatitis-b in pregnant women and their neonatal outcome
International Journal of Medical and Health Research ISSN: 2454-9142, Impact Factor: RJIF 5.54 www.medicalsciencejournal.com Volume 3; Issue 2; February 2017; Page No. 126-130 A study on hepatitis-b in
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationTreatment of Hepatitis (and HIV) in Pregnancy 2010
Treatment of Hepatitis (and HIV) in Pregnancy 2010 Douglas T. Dieterich, M.D. Professor of Medicine, Division of Liver Diseases, Director of CME, Department of Medicine, Mt Sinai School of Medicine Zidovudine
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationGive Birth to the End of Hepatitis B
Give Birth to the End of Hepatitis B LiverConnects Feb 14, 2017 Rosalyn Singleton MD MPH Research Physician, ANTHC ris2@cdc.gov risingleton@anthc.org Annie Peterson-Lewis RN State of Alaska Perinatal Hepatitis
More informationReal world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load
Received: 16 July 2018 First decision: 5 August 2018 Accepted: 27 October 2018 DOI: 10.1111/apt.15064 Real world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with
More informationMA PERINATAL HEPATITIS B PREVENTION PROGRAM
MA PERINATAL HEPATITIS B PREVENTION PROGRAM Massachusetts Department of Public Health Immunization Program MIAP 2016 1 1 Presenter Disclosure Information I, Theodora Wohler, have been asked to disclose
More informationChronic hepatitis B in pregnancy: unique challenges and opportunities
The Korean Journal of Hepatology 2011;17:1-8 DOI: 10.3350/kjhep.2011.17.1.1 Review Chronic hepatitis B in pregnancy: unique challenges and opportunities Kumaresan Yogeswaran and Scott K. Fung Department
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationCurrent recommendations of managing HBV infection in preconception or pregnancy
Front. Med. 2014, 8(2): 158 165 DOI 10.1007/s11684-014-0340-4 REVIEW Current recommendations of managing HBV infection in preconception or pregnancy James S. Park, Calvin Pan ( ) Division of Gastroenterology,
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationTelbivudine or Lamivudine Use in Late Pregnancy Safely Reduces Perinatal Transmission of Hepatitis B Virus in Real-Life Practice
VIRAL HEPATITIS Telbivudine or Lamivudine Use in Late Pregnancy Safely Reduces Perinatal Transmission of Hepatitis B Virus in Real-Life Practice Hua Zhang, 1 Calvin Q. Pan, 2 Qiumei Pang, 1 Ruihua Tian,
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationperinatology.com Infections During Pregnancy
perinatology.com Infections During Pregnancy Search Translate Back Site Map Agencies and Organizations Calculators Critical Care Exposures Chemicals Drugs Infection Physical Agent Genetics Images Labs
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationHepatitis B at a Glance
Return completed form, preferably within 30 days of U.S. date of arrival, to address on reverse side of this form. Review overseas medical exam if available and document immunization dates. Indicate if
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationThe Hep B Moms Program: A Primary Care Model for Management of Hepatitis B in Pregnancy
The Hep B Moms Program: A Primary Care Model for Management of Hepatitis B in Pregnancy Janice Lyu, MS Senior Hepatitis B Program Associate Charles B. Wang Community Health Center (CBWCHC) Charles B Wang
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Comparative Effectiveness of Prophylactic Strategies for Perinatal Transmission of Hepatitis B Virus: A Network Meta-analysis of Randomized Controlled Trials
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Comparative Effectiveness of Prophylactic Strategies for Perinatal Transmission of Hepatitis B Virus: A Network Meta-analysis of Randomized Controlled Trials
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationMichigan Guidelines: HIV, Syphilis, HBV in Pregnancy
Michigan Guidelines: HIV, Syphilis, HBV in Pregnancy Presenter: Theodore B. Jones, MD Maternal Fetal Medicine Wayne State University School of Medicine Beaumont Dearborn Hospital HIV, Syphilis, HBV in
More informationPrevention of Infections in Mothers & Infants
Helen Y. Chu, MD MPH Division of Allergy & Infectious Diseases University of Washington Prevention of Infections in Mothers & Infants June 2, 2015 Midwives Association of Washington State Conference Financial
More informationPERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases
PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission
More informationPERICONCEPTION MANAGEMENT OF INFECTIOUS DISEASES - JUNE
PERICONCEPTION MANAGEMENT OF INFECTIOUS DISEASES - JUNE 2017 Julie van Schalkwyk, MD FRCSC Associate Clinical Professor, University of British Columbia Obstetrics and Gynecology BCWH Disclaimer No Conflicts
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis B and pregnancy
Official reprint from UpToDate www.uptodate.com 2017 UpToDate Hepatitis B and pregnancy Authors: Hannah Lee, MD, Anna SF Lok, MD Section Editors: Rafael Esteban, MD, Louise Wilkins-Haug, MD, PhD Deputy
More informationHepatitis B and C Overview, Outbreaks, and Recommendations. Viral Hepatitis Language. Types of Viral Hepatitis 7/1/2013
Hepatitis B and C Overview, Outbreaks, and Recommendations Elizabeth Lawlor, MS Healthy Kansans living in safe and sustainable environments. Viral Hepatitis Language Acute infection is when the infection
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationHepatitis A-E Viruses. Dr Nemes Zsuzsanna
Hepatitis A-E Viruses Dr Nemes Zsuzsanna Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D C Parenterally transmitted HGV, TTV, SEN, other
More informationPERINATAL HEPATITIS B
PERINATAL HEPATITIS B A Prevention Strategy Douglas County Health Department, Omaha, NE Why Prevention is Important About 1.25 million people in the U.S. have chronic hepatitis B infection Hepatitis B
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationViral Hepatitis - Historical Perspective
Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and
More informationAntiviral Therapy for Chronic Hepatitis B in Pregnancy
138 Antiviral Therapy for Chronic Hepatitis B in Pregnancy Calvin Q. Pan, MD 1 Hannah M. Lee, MD 2 1 Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Medical Center, New
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationDoes Hepatitis B Virus Prenatal Transmission Result in Postnatal Immunoprophylaxis Failure?
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2010, p. 1836 1841 Vol. 17, No. 12 1556-6811/10/$12.00 doi:10.1128/cvi.00168-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Does Hepatitis
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationTenofovir for Prevention of Mother-to-Child Transmission of Hepatitis B
J O U R N A L C L U B Tenofovir for Prevention of Mother-to-Child Transmission of Hepatitis B Source Citation: Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. China Study Group for the Mother-to-Child
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationTenofovir and lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus in highly viremic mothers in Vietnam
African Journal of Pregnancy and Childbirth Vol. 2 (1), pp. 010-016, November, 2014. Available online at www.internationalscholarsjournals.org International Scholars Journals Full Length Research Paper
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Volume 12, Issue 4 December, 2013 Overview Prevention of Perinatal Hepatitis B Transmission Perinatal transmission of hepatitis B virus (HBV) is preventable through universal
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationTo provide the guidelines for the management of healthcare workers who have had an occupational exposure to blood and/or body fluids.
TITLE/DESCRIPTION: MANAGEMENT OF OCCUPATIONAL EXPOSURE TO HBV, HCV, and HIV INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All GCC Countries GULF COOPERATION COUNCIL
More informationThe management of hepatitis B virus (HBV) Management of hepatitis B in pregnancy: Weighing the options ABSTRACT PERINATAL TRANSMISSION KEY POINTS
TRAM T. TRAN, MD Associate Professor of Medicine, Geffen ULA School of Medicine Medical Director, Liver Transplantation, enter for Liver Disease and Transplantation, edars-sinai Medical enter Los Angeles,
More informationHepatitis B. Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre
Hepatitis B Introduction Hepatitis B virus is one of the most prevalent viruses worldwide and is a major cause of chronic liver disease and hepatocellular carcinoma. It is a hepadnavirus, consisting of
More informationUniversal immunization beginning at birth and
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 5, 2016 Quantitative Maternal Hepatitis B Surface Antigen Predicts Maternally Transmitted Hepatitis B Virus Infection Wan-Hsin
More informationViral Hepatitis. Background
Viral Hepatitis Background Hepatitis or inflammation of the liver can be caused by infectious and noninfectious problems. Infectious etiologies include viruses, bacteria, fungi and parasites. Noninfectious
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes
More informationHIGH RATE OF HEPATITIS B VIRUS MOTHER-TO-CHILD TRANSMISSION IN LAO PEOPLE S DEMOCRATIC REPUBLIC
HIGH RATE OF HEPATITIS B VIRUS MOTHER-TO-CHILD TRANSMISSION IN LAO PEOPLE S DEMOCRATIC REPUBLIC Prapan Jutavijittum 1, Amnat Yousukh 1, Bounnack Saysanasongkham 2, Bounthome Samountry 3, Khamtim Samountry
More informationAN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS
AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS Thosporn Vimolket 1 and Yong Poovorawan 2 1 Department
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More information1. What are the population benefits of universal screening programs for hepatitis B virus infection in pregnant women?
August 9, 2017 Re: Comments on Draft Research Plan for Hepatitis B Virus Infection in Pregnant Women: Screening To the U.S. Preventive Services Task Force: On behalf of the Association of Asian Pacific
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationPerinatal Hepatitis b Prevention
Perinatal Hepatitis b Prevention Purpose 2 The primary goal of the Perinatal Hepatitis b Prevention Program (PHBPP) is to identify all pregnant women who are infected with hepatitis b and prevent perinatal
More informationHSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3
HSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3 Goals To increase obstetrician knowledge regarding HSV screening Institute clinical changes at
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More information